Trial
NCT04605926
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Biocon Limited
Collaborators
—
Condition
Coronavirus
Intervention
EQ001
Why stopped
Sponsor has currently elected to withhold study initiation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-12